Drug Profile
Research programme: eye disorder therapies - Formosa Pharmaceuticals/Sosei Heptares
Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Activus Pharma; Sosei Heptares
- Developer Activus Pharma; Formosa Pharmaceuticals; Sosei Heptares
- Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Glucocorticoids
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders; Ocular inflammation
- Discontinued Infectious conjunctivitis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Ocular-inflammation in Taiwan (Ophthalmic, Suspension)
- 18 Jul 2019 Formosa Pharmaceuticals plans a first-in-human trial for Ocular inflammation in USA
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares